Amrinone

Amrinone

Clinical data
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intravenous
ATC code	C01CE01 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	10 to 49%
Metabolism	Hepatic
Elimination half-life	5 to 8 hours
Excretion	Renal (63%) and fecal (18%)
Identifiers
IUPAC name 5-amino-3,4'-bipyridin-6(1H)-one
CAS Number	60719-84-8
PubChem CID	3698
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H9N3O
Molar mass	187.198 g/mol

WikiDoc Resources for Amrinone
Articles
Most recent articles on Amrinone Most cited articles on Amrinone Review articles on Amrinone Articles on Amrinone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Amrinone Images of Amrinone Photos of Amrinone Podcasts & MP3s on Amrinone Videos on Amrinone
Evidence Based Medicine
Cochrane Collaboration on Amrinone Bandolier on Amrinone TRIP on Amrinone
Clinical Trials
Ongoing Trials on Amrinone at Clinical Trials.gov Trial results on Amrinone Clinical Trials on Amrinone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Amrinone NICE Guidance on Amrinone NHS PRODIGY Guidance FDA on Amrinone CDC on Amrinone
Books
Books on Amrinone
News
Amrinone in the news Be alerted to news on Amrinone News trends on Amrinone
Commentary
Blogs on Amrinone
Definitions
Definitions of Amrinone
Patient Resources / Community
Patient resources on Amrinone Discussion groups on Amrinone Patient Handouts on Amrinone Directions to Hospitals Treating Amrinone Risk calculators and risk factors for Amrinone
Healthcare Provider Resources
Symptoms of Amrinone Causes & Risk Factors for Amrinone Diagnostic studies for Amrinone Treatment of Amrinone
Continuing Medical Education (CME)
CME Programs on Amrinone
International
Amrinone en Espanol Amrinone en Francais
Business
Amrinone in the Marketplace Patents on Amrinone
Experimental / Informatics
List of terms related to Amrinone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Amrinone (INN) or inamrinone, trade name Inocor, is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

Class: Cardiac inotrope.
Actions: Increases cardiac contractility, vasodilator.
Indications: Short-term management of severe CHF.
Contraindications: Patients with history of hypersensitivity to the drug.
Precautions: May increase myocardial ischemia. Blood pressure, pulse, and EKG should be constantly monitored. Amrinone should only be diluted with normal saline or 1/2 normal saline; no dextrose solutions should be used. Furosemide should not be administered into an IV line delivering Amrinone.
Side Effects: Reduction in platelets, nausea and vomiting cardiac arrhythmias.
Dosage: 0.75 mg/kg bolus given slowly over 2-3 minute interval followed by maintenance infusion of 2-15 µg/kg/minute.
Routes: IV bolus and infusion as described earlier.
Pediatric Dosage: Safety in children has not been established
Template:Phosphodiesterase inhibitors Template:Cardiac stimulants excluding cardiac glycosides

Template:WikiDoc Sources